Empiric Antibiotic Therapy for Patients with Pulmonary I
Empiric Antibiotic Therapy for Patients with Pulmonary I
批准号:
7215798
负责人:
Naomi P O'Grady
金额:
$0.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
beta lactam antibioticdrug administration rate /durationdrug resistancedrug screening /evaluationhospital length of stayhospital patient carehuman subjecthuman therapy evaluationmicroorganism disease chemotherapynosocomial infection controlnosocomial infectionsoutcomes researchpatient oriented researchpneumoniarespiratory disorder chemotherapyrespiratory infections
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Patients with pulmonary infiltrates receive more than half of the antibiotics prescribed in the ICU. Many of these patients receive antibiotics for suspected, but not proven, respiratory infections. Yet many of these patients with abnormal radiographs actually have a non-infectious etiology. Although pneumonia is the most common hospital acquired infection in ICU patients [12], it is difficult to diagnose definitively because the diagnosis relies heavily on radiographic findings that correlate poorly with clinical pneumonia. But because of the attributable mortality associated with nosocomial pneumonia, the risk of missing a treatable infection often outweighs the perception of minimal risk antibiotic therapy. Consequently, overuse or inappropriate use of antibiotics for the treatment of suspected pneumonia is widespread in this subset of patients, and the emergence of antimicrobial resistant bacteria as a result of antibiotic overuse is increasingly common.
This protocol is designed to determine whether short course empiric antibiotic therapy (3 days of meropenem) for patients with new pulmonary infiltrates can reduce the emergence of antimicrobial resistant organisms compared to a standard course of antibiotic therapy (10 days of therapy with antibiotics of the primary care teams choosing). In addition, it will determine whether hospital length of stay can be reduced, hospital cost can be reduced, while morbidity and mortality of patients will not be affected. This protocol targets patients who have new pulmonary infiltrates, yet are at low risk of having pneumonia, as determined using the Clinical Pulmonary Infection score (CPIS).
Progress Report: Final approval from the BAMSG Steering Committee has been obtained. The study has undergone scientific review and is pending IRB review at the Clinical Center. The process of obtaining an IND is underway. The IND is expected by October 31. Ten sites have been selected based on information obtained by survey. An investigators meeting is scheduled for mid-December.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Antibiotic Therapy for Pts with Pulmonary Infiltrates
-
批准号:6825428
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Naomi P O'Grady
-
依托单位:
Empiric Antibiotic Therapy for Patients with Pulmonary I
-
批准号:7332161
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Naomi P O'Grady
-
依托单位:
Strategies to Reduce Transmission of Antimicrobial Resis
-
批准号:7215818
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Naomi P O'Grady
-
依托单位:
Empiric Antibiotic Therapy for Pulmonary Infiltrates
-
批准号:7003971
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Naomi P O'Grady
-
依托单位:
Strategies to Reduce Transmission of Antimicrobial Resis
-
批准号:7332558
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Naomi P O'Grady
-
依托单位:
Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in ICUs
-
批准号:8565322
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Naomi P O'Grady
-
依托单位: